Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Krystal Biotech (KRYS) over the last 4 years, with Q4 2025 value amounting to 48.02%.

  • Krystal Biotech's EBITDA Margin fell 200.0% to 48.02% in Q4 2025 from the same period last year, while for Dec 2025 it was 52.98%, marking a year-over-year increase of 225800.0%. This contributed to the annual value of 52.98% for FY2025, which is 225700.0% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's EBITDA Margin is 48.02%, which was down 200.0% from 81.09% recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's EBITDA Margin registered a high of 1059.99% during Q1 2021, and its lowest value of 0.01% during Q1 2024.
  • For the 4-year period, Krystal Biotech's EBITDA Margin averaged around 212.8%, with its median value being 41.17% (2025).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -9070600bps in 2024, then skyrocketed by 461100bps in 2025.
  • Quarter analysis of 4 years shows Krystal Biotech's EBITDA Margin stood at 1059.99% in 2021, then tumbled by -98bps to 23.04% in 2023, then skyrocketed by 108bps to 48.05% in 2024, then fell by 0bps to 48.02% in 2025.
  • Its last three reported values are 48.02% in Q4 2025, 81.09% for Q3 2025, and 40.71% during Q2 2025.